Procter & Gamble Company (The) $PG Shares Sold by Prostatis Group LLC

Prostatis Group LLC trimmed its position in Procter & Gamble Company (The) (NYSE:PG) by 12.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,304 shares of the company’s stock after selling 335 shares during the period. Prostatis Group LLC’s holdings in Procter & Gamble were worth $367,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of PG. Kingstone Capital Partners Texas LLC boosted its holdings in shares of Procter & Gamble by 655,209.0% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 76,028,952 shares of the company’s stock worth $11,832,680,000 after purchasing an additional 76,017,350 shares during the last quarter. Northern Trust Corp boosted its holdings in shares of Procter & Gamble by 0.8% during the 1st quarter. Northern Trust Corp now owns 29,644,000 shares of the company’s stock worth $5,051,930,000 after purchasing an additional 248,792 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Procter & Gamble by 13.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,480,670 shares of the company’s stock worth $3,660,737,000 after purchasing an additional 2,466,308 shares during the last quarter. Goldman Sachs Group Inc. boosted its holdings in shares of Procter & Gamble by 3.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 17,405,539 shares of the company’s stock worth $2,966,252,000 after purchasing an additional 583,629 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Procter & Gamble by 6.3% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 17,293,428 shares of the company’s stock worth $2,947,146,000 after purchasing an additional 1,018,865 shares during the last quarter. 65.77% of the stock is currently owned by institutional investors and hedge funds.

Procter & Gamble Stock Down 0.6%

Shares of NYSE PG opened at $149.69 on Monday. Procter & Gamble Company has a 52-week low of $149.45 and a 52-week high of $180.43. The business’s 50 day moving average is $155.24 and its two-hundred day moving average is $159.41. The company has a quick ratio of 0.49, a current ratio of 0.70 and a debt-to-equity ratio of 0.49. The firm has a market cap of $350.34 billion, a price-to-earnings ratio of 22.99, a PEG ratio of 3.97 and a beta of 0.36.

Procter & Gamble (NYSE:PG) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.42 by $0.06. Procter & Gamble had a return on equity of 32.69% and a net margin of 18.95%.The business had revenue of $20.89 billion for the quarter, compared to analyst estimates of $20.79 billion. During the same quarter in the prior year, the company earned $1.40 earnings per share. The company’s revenue was up 1.7% on a year-over-year basis. Procter & Gamble has set its FY 2026 guidance at 6.830-7.090 EPS. Research analysts predict that Procter & Gamble Company will post 6.91 EPS for the current year.

Analysts Set New Price Targets

PG has been the topic of several recent research reports. Weiss Ratings restated a “hold (c+)” rating on shares of Procter & Gamble in a report on Wednesday, October 8th. UBS Group reduced their price target on shares of Procter & Gamble from $180.00 to $176.00 and set a “buy” rating on the stock in a research report on Wednesday. Evercore ISI reaffirmed an “in-line” rating and set a $170.00 price target (down previously from $190.00) on shares of Procter & Gamble in a research report on Monday, July 14th. BNP Paribas Exane reduced their price target on shares of Procter & Gamble from $177.00 to $172.00 and set an “outperform” rating on the stock in a research report on Tuesday, September 23rd. Finally, Wells Fargo & Company reduced their price target on shares of Procter & Gamble from $173.00 to $170.00 and set an “overweight” rating on the stock in a research report on Thursday, September 25th. Eleven investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, Procter & Gamble currently has an average rating of “Moderate Buy” and a consensus price target of $172.21.

Insider Buying and Selling at Procter & Gamble

In other news, CFO Andre Schulten sold 4,252 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $152.23, for a total transaction of $647,281.96. Following the sale, the chief financial officer owned 53,992 shares of the company’s stock, valued at approximately $8,219,202.16. This represents a 7.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Balaji Purushothaman sold 490 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $152.23, for a total value of $74,592.70. Following the sale, the insider directly owned 12,616 shares in the company, valued at $1,920,533.68. This represents a 3.74% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 149,763 shares of company stock valued at $23,421,279. Insiders own 0.20% of the company’s stock.

About Procter & Gamble

Procter & Gamble Co engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances.